Logo

Tot Biopharm’s Pusintin (biosimilar, bevacizumab) Receives NMPA’s Marketing Approval for Non-Squamous NSCLC and Metastatic Colorectal Cancer

Share this

Tot Biopharm’s Pusintin (biosimilar, bevacizumab) Receives NMPA’s Marketing Approval for Non-Squamous NSCLC and Metastatic Colorectal Cancer

Shots:

  • The NMPA has approved Pusintin for marketing in mainland China (Ex-Hong Kong, Macau, and Taiwan regions) for the treatment of patients with advanced, metastatic, or recurrent nsq.NSCLC  and mCRC
  • In non-clinical/ clinical studies, Pusintin showed similar PK characteristics as originator drug and clinically equivalent with high similarity in safety and immunogenicity
  • Pusintin marks the 1st marketing-approved biosimilar of Avastin in China. The company has commercial-scale manufacturing operations in Suzhou Industrial Park. For Pusintin, company acquires the Perfusion-batch mixed culture technology (PB-Hybrid Technology) for commercial production

Ref: PR Newswire | Image: Tot Biopharm

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions